Fig. 1: Patient selection flowchart in cohort study. | Nature Communications

Fig. 1: Patient selection flowchart in cohort study.

From: Effectiveness and safety of continuous low-molecular-weight heparin versus switching to direct oral anticoagulants in cancer-associated venous thrombosis

Fig. 1

Cohort selection for analyzing the effectiveness and safety of continuous low-molecular-weight heparin (LMWH) versus switching to direct oral anticoagulants (DOACs) among patients with cancer-associated venous thrombosis (CAT). Switchers were defined as patients who switched to DOACs (apixaban, dabigatran, edoxaban, or rivaroxaban) after receiving LMWH (enoxaparin, tinzaparin, or nadroparin) treatment for any duration. Non-switchers were defined as patients who consistently received LMWH.

Back to article page